MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Glaukos Corp

Chiusa

SettoreSettore sanitario

87.46 4.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

83.83

Massimo

87.46

Metriche Chiave

By Trading Economics

Entrata

-1.5M

-20M

Vendite

17M

124M

Margine di Profitto

-15.837

Dipendenti

995

EBITDA

12M

-8.6M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+39.23% upside

Dividendi

By Dow Jones

Utili prossimi

3 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-762M

4.7B

Apertura precedente

83.45

Chiusura precedente

87.46

Notizie sul Sentiment di mercato

By Acuity

77%

23%

354 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Glaukos Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ott 2025, 16:58 UTC

Utili

BMW Trims 2025 View, Citing Weaker Performance in China

7 ott 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 ott 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 ott 2025, 23:19 UTC

Discorsi di Mercato

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 ott 2025, 22:40 UTC

Discorsi di Mercato

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 20:44 UTC

Azioni calde

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 ott 2025, 19:42 UTC

Discorsi di Mercato

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 ott 2025, 19:23 UTC

Acquisizioni, Fusioni, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 ott 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 ott 2025, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 ott 2025, 15:33 UTC

Discorsi di Mercato

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 ott 2025, 15:25 UTC

Discorsi di Mercato

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 ott 2025, 15:15 UTC

Discorsi di Mercato

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 ott 2025, 14:52 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

Glaukos Corp Previsione

Obiettivo di Prezzo

By TipRanks

39.23% in crescita

Previsioni per 12 mesi

Media 117.08 USD  39.23%

Alto 165 USD

Basso 92 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Glaukos Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

11

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

87.61 / 93Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

354 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat